Ultragenyx Pharmaceutical (NASDAQ:RARE) CEO Sells $1,240,411.20 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the transaction, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. This represents a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ultragenyx Pharmaceutical Stock Down 4.1%

NASDAQ:RARE traded down $0.95 on Tuesday, reaching $22.07. 1,722,117 shares of the company’s stock were exchanged, compared to its average volume of 2,531,557. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -3.78 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.41 and a 52-week high of $42.37. The business has a fifty day moving average of $24.06 and a 200-day moving average of $29.30.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. During the same quarter last year, the firm posted ($1.39) EPS. The company’s revenue for the quarter was up 25.5% on a year-over-year basis. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Assetmark Inc. grew its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares during the period. Huntington National Bank raised its position in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S acquired a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $39,000. Smartleaf Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the period. Finally, Covestor Ltd increased its position in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 369 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RARE shares. Wells Fargo & Company reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, December 30th. Truist Financial decreased their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. TD Cowen lowered their target price on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Bank of America lowered their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, January 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 21st. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: TD Cowen conference presentation transcript (information-only; may provide product/program updates but not a direct catalyst). Ultragenyx Presents at TD Cowen — Transcript
• Negative Sentiment: Rosen Law Firm reminder: investors who bought RARE between Aug 3, 2023 and Dec 26, 2025 may pursue lead-plaintiff status; April 6, 2026 deadline highlighted. This amplifies litigation visibility and potential damages exposure. RARE Investors Have Opportunity to Lead — PR Newswire
• Negative Sentiment: GlobeNewswire/Rosen notice with same class-period and April 6, 2026 deadline — reiterates push for lead-plaintiff claims and keeps legal risk top-of-mind for investors. Rosen — GlobeNewswire
• Negative Sentiment: Pomerantz investor alert: class action filed and investors with losses are urged to contact the firm — another solicitation increasing media noise and potential class size. Pomerantz — GlobeNewswire
• Negative Sentiment: Kessler Topaz filing notice: securities-fraud class action filed; one Kessler notice references a March 13, 2026 lead-plaintiff deadline (investors should note differing deadlines across notices). Allegations mention material misstatements/omissions about setrusumab. Kessler Topaz — GlobeNewswire
• Negative Sentiment: Schall Law Firm reminder: encourages investors who bought during the class period to contact the firm before April 6, 2026 — adds to cumulative solicitor activity. Schall Law Firm — GlobeNewswire
• Negative Sentiment: Gross Law Firm notice urging shareholders who lost money to join class action — further publicity that can pressure sentiment. Gross Law Firm — PR Newswire
• Negative Sentiment: Additional Rosen notice via Newsfile reiterating the April 6, 2026 deadline — duplicate outreach increases reach and potential claimant pool. Rosen — Newsfile
• Negative Sentiment: Kessler Topaz/PR notice (PR Newswire duplicate) highlighting class action and setrusumab-related allegations; again points to investor recovery options and legal costs risk. Kessler Topaz — PR Newswire
• Negative Sentiment: Robbins Geller Rudman & Dowd (RGRD) announcement: investors with substantial losses can seek lead-plaintiff appointment by April 6, 2026 — another major firm joining solicitations. RGRD — GlobeNewswire
• Negative Sentiment: PR Newswire Schall Law Firm duplicate: reiterates claims and encourages contact before April 6 — continued repetition in the media cycle. Schall — PR Newswire
• Negative Sentiment: DJS Law Group notice: Ultragenyx sued for securities-law violations; adds to the roster of firms soliciting claims and increasing potential litigation costs and distraction. DJS Law Group — PR Newswire

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.